Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21

This article was originally published in The Pink Sheet Daily

Executive Summary

Less than 1% of outstanding shares had been tendered as of Dec. 10 deadline.

You may also be interested in...



Sanofi And Genzyme Move Closer To A Deal

Companies enter confidentiality agreement allowing Sanofi to conduct due diligence and reportedly have agreed on outlines of a deal.

Sanofi And Genzyme Move Closer To A Deal

Companies enter confidentiality agreement allowing Sanofi to conduct due diligence and reportedly have agreed on outlines of a deal.

Genzyme Builds New Manufacturing Facility As Takeover Deadline Approaches

Belgium-based plant will be used to manufacture Myozyme and Lumizyme for Pompe disease, a franchise that Genzyme says has the potential to become a blockbuster.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel